- Patients with ovarian, cervical, colon, gastric/gastroesophageal junction, non-small cell lung, renal cell, bladder, sarcoma, and prostate cancer that is known to be HER2 1+, 2+ or 3+ by IHC OR have a Vysis FISH result > 1.8.